BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 22295149)

  • 1. Primary central nervous system B cell lymphoma with features intermediate between diffuse large B cell lymphoma and Burkitt lymphoma.
    Jiang L; Li Z; Finn LE; Personnet DA; Edenfield B; Foran JM; Jaeckle KA; Reimer R; Menke DM; Ketterling RP; Tun HW
    Int J Clin Exp Pathol; 2012; 5(1):72-6. PubMed ID: 22295149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.
    Snuderl M; Kolman OK; Chen YB; Hsu JJ; Ackerman AM; Dal Cin P; Ferry JA; Harris NL; Hasserjian RP; Zukerberg LR; Abramson JS; Hochberg EP; Lee H; Lee AI; Toomey CE; Sohani AR
    Am J Surg Pathol; 2010 Mar; 34(3):327-40. PubMed ID: 20118770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rare cases of primary central nervous system anaplastic variant of diffuse large B-cell lymphoma.
    Xu T; Jia Q; Wang Y; Liu Y; Han D; Li P; Ma J; Fan L; Yan Q; Guo S; Li M; Wang Z
    Diagn Pathol; 2019 May; 14(1):45. PubMed ID: 31109360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Survival of patients with primary central nervous system diffuse large B-cell lymphoma: impact of gene aberrations and protein overexpression of bcl-2 and C-MYC, and selection of chemotherapy regimens].
    Yin WJ; Zhu X; Yang HY; Sun WY; Wu MJ
    Zhonghua Bing Li Xue Za Zhi; 2018 Jan; 47(1):32-38. PubMed ID: 29325248
    [No Abstract]   [Full Text] [Related]  

  • 5. MYC, BCL2, and BCL6 rearrangements in primary central nervous system lymphoma of large B cell type.
    Nosrati A; Monabati A; Sadeghipour A; Radmanesh F; Safaei A; Movahedinia S
    Ann Hematol; 2019 Jan; 98(1):169-173. PubMed ID: 30306208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A highly therapy-resistant case of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma showing strong BCL2 staining, otherwise indistinguishable from Burkitt lymphoma.
    Kurita N; Nishikii H; Nakamoto R; Nakamura N; Kondo Y; Okoshi Y; Suzukawa K; Hasegawa Y; Yokoyama Y; Noguchi M; Chiba S
    J Clin Exp Hematop; 2011; 51(1):37-42. PubMed ID: 21628859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [B-cell lymphomas with concurrent myc and bcl-2/IgH or bcl-6 translocations].
    Luo DL; Liu YH; Zhang F; Xu FP; Yan LX; Chen J; Xu J; Luo XL; Zhuang HG
    Zhonghua Bing Li Xue Za Zhi; 2013 Sep; 42(9):584-8. PubMed ID: 24314242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Double-hit B-cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B-cell lymphomas.
    Pillai RK; Sathanoori M; Van Oss SB; Swerdlow SH
    Am J Surg Pathol; 2013 Mar; 37(3):323-32. PubMed ID: 23348205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contribution of immunophenotype to the investigation and differential diagnosis of Burkitt lymphoma, double-hit high-grade B-cell lymphoma, and single-hit MYC-rearranged diffuse large B-cell lymphoma.
    Tsagarakis NJ; Papadhimitriou SI; Pavlidis D; Liapis K; Gortzolidis G; Kostopoulos IV; Marinakis T; Paterakis G
    Cytometry B Clin Cytom; 2020 Sep; 98(5):412-420. PubMed ID: 32497402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Central nervous system infiltration of a multiple cytokine-producing double-hit B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma with CC chemokine receptor 7 expression.
    Nakayama S; Yokote T; Iwaki K; Hiraoka N; Hirata Y; Akioka T; Miyoshi T; Takayama A; Nishiwaki U; Masuda Y; Tsuji M; Hanafusa T
    Acta Oncol; 2013 Aug; 52(6):1217-20. PubMed ID: 23205745
    [No Abstract]   [Full Text] [Related]  

  • 11. Aggressive B cell lymphomas of the gastrointestinal tract: clinicopathologic and genetic analysis.
    Choi SY; Kim SJ; Kim WS; Kim K; Ko YH
    Virchows Arch; 2011 Nov; 459(5):495-502. PubMed ID: 22002677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triple-hit B-cell Lymphoma With MYC, BCL2, and BCL6 Translocations/Rearrangements: Clinicopathologic Features of 11 Cases.
    Wang W; Hu S; Lu X; Young KH; Medeiros LJ
    Am J Surg Pathol; 2015 Aug; 39(8):1132-9. PubMed ID: 25828391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary central nervous system diffuse large B-cell lymphoma shows an activated B-cell-like phenotype with co-expression of C-MYC, BCL-2, and BCL-6.
    Li X; Huang Y; Bi C; Yuan J; He H; Zhang H; Yu Q; Fu K; Li D
    Pathol Res Pract; 2017 Jun; 213(6):659-665. PubMed ID: 28552541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma.
    Landsburg DJ; Petrich AM; Abramson JS; Sohani AR; Press O; Cassaday R; Chavez JC; Song K; Zelenetz AD; Gandhi M; Shah N; Fenske TS; Jaso J; Medeiros LJ; Yang DT; Nabhan C
    Cancer; 2016 Feb; 122(4):559-64. PubMed ID: 26565895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Doublehit lymphomas -  review of the literature and case report].
    Smardová J; Moulis M; Lišková K; Koptíková J; Hrabálková R; Klusáková J
    Klin Onkol; 2014; 27(1):24-32. PubMed ID: 24635434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary central nervous system lymphomas associated with chronic inflammation: diagnostic pitfalls of central nervous system lymphomas.
    Sugita Y; Masuoka J; Kameda K; Takahashi K; Kimura Y; Higaki K; Furuta T; Ohshima K
    Brain Tumor Pathol; 2020 Oct; 37(4):127-135. PubMed ID: 32627089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathological features of double-hit B-cell lymphomas with MYC and BCL2, BCL6 or CCND1 rearrangements.
    Yoshida M; Ichikawa A; Miyoshi H; Kiyasu J; Kimura Y; Arakawa F; Niino D; Ohshima K
    Pathol Int; 2015 Oct; 65(10):519-27. PubMed ID: 26224092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of the GMALL-B-ALL/NHL2002 protocol in Burkitt leukemia/lymphoma and aggressive non-Hodgkin-lymphomas with or without CNS involvement.
    Sakarou M; Eisele L; Dührsen U; Hüttmann A
    Eur J Haematol; 2019 Mar; 102(3):241-250. PubMed ID: 30471148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Burkitt lymphoma (BL): reclassification of 39 lymphomas diagnosed as BL or Burkitt-like lymphoma in the past based on immunohistochemistry and fluorescence in situ hybridization.
    Kodet R; Mrhalová M; Stejskalová E; Kabícková E
    Cesk Patol; 2011 Jul; 47(3):106-14. PubMed ID: 21887927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miR expression in MYC-negative DLBCL/BL with partial trisomy 11 is similar to classical Burkitt lymphoma and different from diffuse large B-cell lymphoma.
    Zajdel M; Rymkiewicz G; Chechlinska M; Blachnio K; Pienkowska-Grela B; Grygalewicz B; Goryca K; Cieslikowska M; Bystydzienski Z; Swoboda P; Walewski J; Siwicki JK
    Tumour Biol; 2015 Jul; 36(7):5377-88. PubMed ID: 25677902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.